Congenital Cytomegalovirus Infection. New Prospects for Prevention and Therapy.

Research output: Contribution to journalReview article

94 Scopus citations

Abstract

Cytomegalovirus is the commonest congenital viral infection in the developed world, with an overall prevalence of approximately 0.6%. Approximately 10% of congenitally infected infants have signs and symptoms of disease at birth, and these symptomatic infants have a substantial risk of subsequent neurologic sequelae. These include sensorineural hearing loss, mental retardation, microcephaly, development delay, seizure disorders, and cerebral palsy. Antiviral therapy for children with symptomatic congenital cytomegalovirus infection is effective at reducing the risk of long-term disabilities and should be offered to families with affected newborns. An effective preconceptual vaccine against CMV could protect against long-term neurologic sequelae and other disabilities.

Original languageEnglish (US)
Pages (from-to)335-349
Number of pages15
JournalPediatric clinics of North America
Volume60
Issue number2
DOIs
StatePublished - Apr 1 2013

    Fingerprint

Keywords

  • Antiviral therapy
  • CMV vaccines
  • Congenital cytomegalovirus (CMV) infection
  • Newborn screening
  • Sensorineural hearing loss

Cite this